Visa Introduces Team Visa Roster Ahead of the Olympic and Paralympic Games Tokyo 2020
13.11.2019 15:00:00 EET | Business Wire | Press release
Visa (NYSE: V), the Worldwide Payment Technology Partner of the Olympic and Paralympic Games, today announced its most diverse roster of athletes on Team Visa Tokyo 2020. Representing 43 countries, the most in Team Visa history, the current roster is comprised of 70+ athletes across 30+ sports, including new additions to The Games: Surfing, Skateboarding and Sport Climbing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191113005219/en/
Visa Introduces Team Visa Roster Ahead of the Olympic and Paralympic Games Tokyo 2020 (Graphic: Business Wire)
The announcement was made at the Team Visa Summit, hosted at the company’s San Francisco Innovation Center. The Summit offers athletes resources on how to improve financial literacy, benefit from digital payments and elevate their personal brand.
“As one of the longest standing partners of the Olympic and Paralympic Games, Visa looks forward to Tokyo 2020. Set to be the largest Games yet, Tokyo 2020 will feature 7,000 hours of broadcast programming and three billion minutes of streamed content,” said Chris Curtin, chief brand and innovation marketing officer, Visa. “Our Team Visa Tokyo 2020 roster reflects The Games themselves: globally diverse, representative of new emerging sports and larger than ever. We are proud to reveal this year’s Team Visa roster and support these athletes as go for Gold in Tokyo.”
The Team Visa Tokyo 2020 roster includes decorated Olympians (Simone Biles, Gymnastics, USA, Katie Ledecky, Swimming, USA, Daniel Dias, Para Swimming, Brazil and Yelyzaveta Mereshko, Para Swimming, Ukraine), World Champions (Megan Rapinoe, Football, USA, PV Sindhu, Badminton, India, Mariana Pajón, BMX, Colombia and Oksana Masters, Para Cycling, USA) and 16 first-time Olympic and Paralympic hopefuls (Kanoa Igarashi, Surfing, Japan and Poppy Starr Olsen, Skateboarding, Australia and Sean McColl, Sport Climbing, Canada, among others). View the current Team Visa roster for Tokyo 2020 here.
“I am honored to join Team Visa and share the spirit of The Games with these incredible athletes as we prepare for Tokyo 2020," said Simone Biles, four-time Olympic gold medalist, Gymnastics, USA. “The opportunity to compete on the world stage while representing our country is truly an honor, and the encouragement and support we receive from teammates, family, friends, fans and our partners, like Visa, really means a lot as we pursue our lifelong goals and dreams.”
“The Team Visa Summit is a great opportunity to meet and interact with my peers in advance of The Games,” said Kanoa Igarashi, Surfing, Japan. “In hoping to compete at my first Olympic Games, having a family of athletes in Team Visa will help me feel more at home knowing I have a sense of community by my side.”
Team Visa Tokyo 2020
Founded in 2000, Team Visa has championed nearly 500 athletes. Each has been selected based on athletic achievements, character and personal journey, and are representative of many of Visa’s brand values and priorities, including:
- Gender Equality: Since the beginning of Team Visa, on average 54% of Team Visa have been women, including the 41 women athletes for Tokyo 2020, underscoring Visa’s efforts to empower more women athletes and support the development of women’s sports.
- Social Impact: In addition to excelling in their sport, many Team Visa athletes advocate for organizations that help to positively impact their local communities. Alison Cerutti (Beach Volleyball, Brazil) has an organization in Brazil that helps give underserved children in his community access to sports, health services and more. Erick Barrondo (Athletics, Guatemala) has demonstrated a similar dedication to helping youth through a charitable race walk he and his wife started to benefit impoverished children in Guatemala.
- Small Business: Visa is a true advocate for the 30 million small businesses in the U.S. and extends that commitment to its Team Visa athletes. From 19-year-old Poppy Starr Olsen (Skateboarding, Australia), an artist and jewelry maker who has leveraged her business to fund her athletic career, to Megan Rapinoe (Football, USA), whose on-field passion is matched by a commitment to growing her purposeful fashion company, Visa is dedicated to supporting athletes in their businesses endeavors.
To learn more about Visa’s ongoing support of Olympic and Paralympic athletes, visit Visa’s Olympic partnership page.
About Visa Inc.
Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of digital commerce on any device, for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa, visa.com/blog and @VisaNews.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191113005219/en/
Contact information
Media Contacts:
Visa | Sheerin Salimi | shesalim@visa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
